Clinical trials investigated the effect of the TGF-β inhibitor galunisertib, either alone or in combination with other therapeutic strategies, in the treatment of advanced or metastatic PC (Melisi et al., 2018; Melisi et al., 2021). This evidence concerns the gene TGFB1 and pachyonychia congenita.